ok thanks for clarifying. How do you see opt performing against eyelea? Is it risky for opt to test phase 3 against eyelea without any solid previous evidence on effectiveness beyond eyelea baseline ?
Ann: Security Class Reinstatement to Quotation- OPTOB, page-20
-
- There are more pages in this discussion • 305 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
79.5¢ |
Change
-0.010(1.24%) |
Mkt cap ! $978.7M | |||
| Open | High | Low | Value | Volume |
| 81.0¢ | 81.0¢ | 78.8¢ | $1.042M | 1.308M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1823 | 79.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 80.0¢ | 22000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |